Assessment of Skeletal Maturity Using Proximal Femoral Epiphysis in Patients With Scoliosis
Launched by THE UNIVERSITY OF HONG KONG · Feb 5, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how to assess bone growth in patients with idiopathic scoliosis, a condition where the spine curves abnormally. Researchers want to see if examining a specific part of the hip bone, called the proximal femoral head, can help determine when a child or teenager has finished growing. This information is important because it can help doctors make better decisions about treatment for scoliosis. The study will create a grading system to measure skeletal maturity and will check if this system is reliable for use in a medical setting.
To participate in the trial, you need to be diagnosed with idiopathic scoliosis and have certain growth plates in your bones that are still open. Unfortunately, if you have scoliosis due to another cause, or if you have a growth hormone deficiency or developmental delays, you wouldn't qualify to join. The trial is currently looking for participants aged between 2 and 65 years, and both boys and girls can take part. If you join, you can expect to have your bone growth assessed through imaging and other evaluations, contributing to important research that may improve care for patients with scoliosis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Idiopathic scoliosis
- • Open triradiate cartilage or open distal radius epiphysis without capping
- Exclusion Criteria:
- • Non-idiopathic scoliosis
- • Patients with growth hormone deficiency or developmental delay
- • Patient has not reached skeletal maturity
- • Defaulted and lost to follow-up
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials